Rituximab in combination with chemotherapy has shown efficacy in patients with diffuse large B-cell lymphoma (DLBCL) for more than 15 years. HLX01 was developed as the rituximab biosimilar following a stepwise approach to demonstrate biosimilarity in analytical, pre-clinical, and clinical investigations to reference rituximab. With demonstrated pharmacokinetic similarity, a phase 3 multi-center, randomized, parallel, double-blind study (HLX01-NHL03) was subsequently conducted to compare efficacy and safety between HLX01 plus cyclophosphamide, doxorubicin, vincristine, and prednisone (H-CHOP) and reference rituximab plus CHOP (R-CHOP) in a total of 407 treatment-naïve, CD20-positive DLBCL patients aged 18–80 years. The primary efficacy endpoint was best overall response rate (ORR) within six cycles of treatment in the per-protocol set (PPS). Secondary endpoints included 1-year efficacy outcomes, safety, and immunogenicity profile. The results showed difference in ORRs [H-CHOP 94.1%; R-CHOP 92.8%] between two treatment groups was 1.4% (95% confidence interval [CI], − 3.59 to 6.32, p = 0.608) which falls within the pre-defined equivalence margin of ± 12%. The safety profile was comparable between the treatment groups, with a similar overall incidence of treatment-emergent adverse events (H-CHOP 99.5%, R-CHOP 99.0%, p = 1.000) and serious adverse events (H-CHOP 34.0%, R-CHOP 32.5%, p = 0.752). This study established bioequivalence in efficacy and safety between HLX01 and reference rituximab. The trial was registered at http://www.chinadrugtrials.org.cn on 26 August 2015 [#CTR20150583].
Hinweise
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
R-CHOP
Rituximab plus cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine), and prednisone
DLBCL
Diffuse large B-Cell lymphoma
H-CHOP
HLX01 plus cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine), and prednisone
ORR
Best overall response rate
PPS
Per-protocol set
CI
Confidence interval
FAS
Full analysis set
AE
Adverse event
IRR
Infusion-related reaction
HBV
Hepatitis B virus
ADA
Anti-drug antibody
Treatment with rituximab, a monoclonal antibody against CD20, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has been used in patients with diffuse large B-cell lymphoma (DLBCL) for more than 15 years with proven efficacy and safety [1]. With demonstrated highly similar analytical characterization and bioequivalence in pharmacokinetics and pharmacodynamics [2], we conducted this phase 3, multi-center, randomized, parallel, double-blind study (HLX01-NHL03) to establish the equivalence in clinical efficacy, safety, and immunogenicity between HLX01 plus CHOP (H-CHOP) and R-CHOP every 21 days for up to six cycles in treatment-naïve patients with CD20-positive DLBCL.
Eligible patients were treatment-naïve adults (≥ 18 to ≤ 80 years) with International Prognostic Index of 0-2, clinical stages I–IV (Ann Arbor Staging) and histologically confirmed CD20-positive DLBCL. The primary efficacy endpoint was best overall response rate (ORR) within six cycles of treatment in the per-protocol set (PPS), and secondary efficacy endpoints included complete response rate, 1-year duration of response, 1-year event-free survival, 1-year progression-free survival, 1-year disease-free survival, 1-year overall survival, and depletion of CD19-positive B-cells in peripheral blood.
Anzeige
From October 9, 2015 to March 10, 2017, a total of 560 patients were screened, of whom 407 patients were randomized (1:1) at 33 investigational sites; 361 patients (H-CHOP 173; R-CHOP 188) completed six cycles of treatment, and 328 patients (H-CHOP 157; R-CHOP 171) completed the study (Fig. 1a). Baseline characteristics are well balanced between two treatment groups (Fig. 1b). In the PPS, the best ORRs within six cycles of treatment in the PPS were 94·1% (95% confidence interval [CI], 89.77 to 97.04) and 92·8% (95% CI, 88.19 to 96.00) in the H-CHOP and R-CHOP groups, respectively, with an intergroup difference of 1.4% (95% CI, − 3.59 to 6.32, p = 0.608). The efficacy equivalence between HLX01 and reference rituximab was demonstrated with 95% CIs falls entirely within the pre-defined margin of ± 12%. The results of using the full analysis set (FAS) were consistent with the primary efficacy analysis in the PPS. Previous reports of R-CHOP in patients with DLBCL have shown ORRs ranging between 83% and 88% [3, 4], which is comparable with the result from this study. No significant differences were observed in the 1-year analysis of all secondary efficacy endpoints, in either the PPS or the FAS (Table 1).
Fig. 1
a Patient disposition of all screened patients. b Baseline patient demographics and disease status of full analysis dataset (FAS)
Table 1
Efficacy outcomes
Per-protocol dataset
Full analysis dataset
H-CHOP (n = 188)
R-CHOP (n = 194)
P value
H-CHOP (n = 199)
R-CHOP (n = 203)
P value
Best overall response rate
177 (94·1)
180 (92·8)
0·608
184 (92·5)
187 (92·1)
0·839
Complete response
88 (46·8)
101 (52·1)
0·231
90 (45·2)
104 (51·2)
0·190
Partial response
89 (47·3)
79 (40·7)
94 (47·2)
83 (40·9)
Stable disease
8 (4·3)
13 (6·7)
11 (5·5)
15 (7·4)
Disease progression
2 (1·1)
1 (0·5)
2 (1·0)
1 (0·5)
No evidence of disease
1 (0·5)
0
2 (1·0)
0
Duration of response
Patients experiencing events
25 (13·8)
21 (11·5)
0·424
26 (13·7)
21 (11·1)
0·355
Patients censored
156 (86·2)
161 (88·5)
164 (86·3)
168 (88·9)
Event-free survival
Patients experiencing events
80 (42·6)
67 (34·5)
0·125
88 (44·2)
71 (35·0)
0·087
Patients censored
108 (57·4)
127 (65·5)
111 (55·8)
132 (65·0)
1-year event-free survival rate
55·4 (47·9, 63·0)
64·5 (57·6, 71·4)
53·7 (46·4, 61·0)
63·4 (56·6, 70·2)
Progression-free survival
Patients experiencing events
31 (16·5)
29 (14·9)
0·534
33 (16·6)
30 (14·8)
0·473
Patients censored
157 (83·5)
165 (85·1)
166 (83·4)
173 (85·2)
1-year progression-free survival rate
75·0 (66·5, 83·6)
80·1 (73·5, 86·7)
74·1 (65·6, 82·7)
79·7 (73·1, 86·3)
Overall survival
Patient deaths
15 (8·0)
13 (6·7)
0·661
16 (8·0)
14 (6·9)
0·701
Patients censored
173 (92·0)
181 (93·3)
183 (92·0)
189 (93·1)
1-year overall survival rate
91·8 (87·8, 95·8)
92·4 (88·3, 96·6)
91·6 (87·6, 95·5)
92·1 (88·0, 96·3)
Disease-free survival
Patients experiencing events
27 (14·4)
24 (12·4)
0·462
28 (14·1)
25 (12·3)
0·477
Patients censored
161 (85·6)
170 (87·6)
171 (85·9)
178 (87·7)
1-year disease-free survival rate
77·4 (68·9, 85·9)
83·0 (76·7, 89·3)
76·9 (68·4, 85·4)
82·6 (76·2, 88·9)
Data are n (%) or %, (95% CI). Percentage values may not total 100% because of rounding
×
The safety analysis set (Table 2) comprised 406 patients who received at least one treatment. 199/200 in H-CHOP group and 204/206 in R-CHOP group (H-CHOP 99.5%, R-CHOP 99.0%, p = 1.000) experienced at least one treatment-emergent adverse event; 68/200 in H-CHOP and 67/206 in R-CHOP (H-CHOP 34.0%, R-CHOP 32.5%, p = 0.752) experienced at least one serious adverse event; 14/200 in H-CHOP and 9/206 in R-CHOP (H-CHOP 7.0%, R-CHOP 4.4%, p = 0.252) discontinued treatment because of adverse events (AEs). The most common AEs were hematological events such as decreased white blood cell count (H-CHOP 85.5%; R-CHOP 85.9%), decreased neutrophil count (H-CHOP 79.0%; R-CHOP 81.6%), and anemia (H-CHOP 38.5%; R-CHOP 35.0%).
Table 2
Safety profiles in the safety analysis dataset
H-CHOP (n = 200)
R-CHOP (n = 206)
Patients with ≥1 TEAE
199 (99·5)
204 (99·0)
Patients with ≥1 SAE
68 (34·0)
67 (32·5)
Patients with ≥1 AE leading to treatment discontinuation
14 (7)
9 (4·4)
Patients deaths due to AE
5 (2·5)
3 (1·5)
Adverse events with an incidence ≥10%
Hematological
Decreased white blood cell count
171 (85·5)
177 (85·9)
Decreased neutrophil count
158 (79·0)
168 (81·6)
Anemia
77 (38·5)
72 (35·0)
Decreased platelet count
34 (17·0)
19 (9·2)
Decreased lymphocyte count
24 (12·0)
34 (16·5)
Decreased hemoglobin concentration
23 (11·5)
20 (9·7)
Non-hematological
Nausea
46 (23·0)
49 (23·8)
Increased alanine aminotransferase
49 (24·5)
38 (18·4)
Fever
47 (23·5)
34 (16·5)
Decreased appetite
32 (16·0)
42 (20·4)
Increased lactate dehydrogenase
30 (15·0)
40 (19·4)
Debilitation
38 (19·0)
31 (15·0)
Alopecia
35 (17·5)
34 (16·5)
Increased aspartate aminotransferase
34 (17·0)
30 (14·6)
Cough
31 (15·5)
26 (12·6)
Vomiting
22 (11·0)
30 (14·6)
Upper respiratory tract infection
19 (9·5)
29 (14·1)
Hypokalemia
28 (14·0)
17 (8·3)
Constipation
27 (13·5)
25 (12·1)
Non-infectious pneumonia
19 (9·5)
24 (11·7)
Pulmonary infection
19 (9·5)
24 (11·7)
Diarrhea
16 (8·0)
22 (10·7)
Chills
20 (10·0)
14 (6·8)
Adverse events by CTCAE Grade
Grade 1
8 (4·0)
6 (2·9)
Grade 2
35 (17·5)
35 (17·0)
Grade 3
54 (27·0)
75 (36·4)
Grade 4
98 (49·0)
85 (41·3)
Grade 5
4 (2·0)
3 (1·5)
Grade 4 adverse events with an incidence ≥2·5%
Decreased neutrophil count
85 (42·5)
75 (36·4)
Decreased white blood cell count
44 (22·0)
42 (20·4)
Febrile neutropenia
5 (2·5)
6 (2·9)
Bone marrow failure
5 (2·5)
5 (2·4)
Data are n (%). Percentage values may not total 100% because of rounding
Among the patients observed with infusion-related reactions (IRRs), 61/200 in H-CHOP group and 61/206 in R-CHOP group (H-CHOP 30.5%; R-CHOP 29.6%), the most common reactions were those affecting skin and subcutaneous tissues. Most IRRs were grade 1 or 2, and no grade 4 or 5 IRRs were reported. Increases in hepatitis B virus (HBV) DNA titer were observed in five patients in H-CHOP group and eight patients in R-CHOP group, and nine of whom were receiving antiviral therapy for chronic HBV; however, no patients developed signs or symptoms of fulminant hepatitis.
Anti-drug antibodies (ADAs) were detected in one patient (< 1%) in each treatment group at baseline and immediately before administration of the second treatment cycle. After 6 months of follow-up, ADAs were detected in one patient in H-CHOP group and two patients in R-CHOP group (H-CHOP 1.0%, R-CHOP 1.7%, p = 1.000), and after 8 months of follow-up in seven patients in H-CHOP group and six patients in R-CHOP group (H-CHOP 7.1%, R-CHOP 5.5%, p = 0.629). During the entire study, only one patient in R-CHOP group had both ADAs and neutralizing antibodies.
Anzeige
In conclusion, this study demonstrated therapeutic equivalence between HLX01 and reference rituximab. The analysis of the primary and secondary efficacy endpoints did not reveal any statistically significant differences between two treatment groups. The safety and immunogenicity profiles of HLX01 were comparable with reference rituximab with no clinically meaningful differences observed between two treatment groups.
Acknowledgements
We thank all the patients and families who were involved in the HLX01-NHL03 study and the clinical study teams and Hangzhou Tigermed Consulting Co., Ltd. for providing support for the study.
Ethics approval and consent to participate
The protocol was developed by the sponsor of the study, Shanghai Henlius Biotech, Inc. The study protocol was reviewed and approved by the relevant independent ethics committee at each participating study center. Written informed consent was obtained from all study participants prior to screening. Data were collected by the site investigators who vouch for the completeness and accuracy of the data and the fidelity of the trial to the protocol. The sponsor analyzed the data. The study was conducted in accordance with the Declaration of Helsinki, Guideline for Good Clinical Practice, and applicable national and local regulations for clinical trials.
Consent for publication
Not applicable.
Competing interests
CMM, JCC, KC, AL, EL, and XZ are employees of Shanghai Henlius Biotech, Inc. All other authors declare no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
verfasst von
Yuankai Shi Yongping Song Yan Qin Qingyuan Zhang Xiaohong Han Xiaonan Hong Dong Wang Wei Li Yang Zhang Jifeng Feng Jianmin Yang Huilai Zhang Chuan Jin Yu Yang Jianda Hu Zhao Wang Zhengming Jin Hang Su Huaqing Wang Haiyan Yang Weijun Fu Mingzhi Zhang Xiaohong Zhang Yun Chen Xiaoyan Ke Li Liu Ding Yu Guo’an Chen Xiuli Wang Jie Jin Tao Sun Xin Du Ying Cheng Pingyong Yi Xielan Zhao Chaoming Ma Jiancheng Cheng Katherine Chai Alvin Luk Eugene Liu Xin Zhang
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
